Five Prime Therapeutics Inc (FPRX) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $-0.49 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.30. Analysts had a consensus of $-0.79. The company posted revenue of $6.50 million in the period, compared to analysts expectations of $6.22 million. The company’s revenue was up 51.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.44 EPS.
Five Prime Therapeutics Inc closed down -2.77 points or -6.12% at $42.51 with 7,06,481 shares getting traded on Wednesday. Post opening the session at $45.01, the shares hit an intraday low of $42.09 and an intraday high of $45.12 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 26, 2016, Marc Belsky (Senior Vice President and CFO) sold 34,102 shares at $49.63 per share price. According to the SEC, on Apr 26, 2016, Franklin M Berger (director) purchased 5,000 shares at $49.54 per share price. On Apr 22, 2016, Lewis T Williams (President, CEO and Chairman) sold 48,671 shares at $48.03 per share price, according to the Form-4 filing with the securities and exchange commission.
Five Prime Therapeutics Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include FPA008 FPA144 and FP-1039/GSK3052230. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1) receptor (CSF1R) that the Company is developing in rheumatoid arthritis. FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b) which the Company is developing to treat patients with gastric cancer. FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation. Its partner GlaxoSmithKline is developing FP-1039/GSK3052230 to treat patients with squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.